| HS Code | 142162 |
| Chemical Name | (S)-3-(4-(2-Chloro-5-iodobenzyl)phenoxy)tetrahydrofuran |
| Molecular Formula | C17H16ClIO2 |
| Molecular Weight | 414.67 g/mol |
| Cas Number | 1807538-89-3 |
| Appearance | White to off-white solid |
| Purity | Typically ≥ 98% |
| Optical Activity | S-enantiomer |
| Smiles | C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)Cl)I |
| Storage Conditions | Store at 2-8°C, in a dry place |
| Solubility | Soluble in DMSO, low solubility in water |
As an accredited (S)-3-(4-(2-Chloro-5-iodobenzyl)phenoxy)tetrahydrofuran factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Amber glass bottle, 1 gram, screw cap, tamper-evident seal, labeled with chemical name, structure, CAS, and hazard information. |
| Container Loading (20′ FCL) | Container Loading (20′ FCL): Securely loading and shipping (S)-3-(4-(2-Chloro-5-iodobenzyl)phenoxy)tetrahydrofuran in 20-foot containers, ensuring chemical safety and compliance. |
| Shipping | This chemical, (S)-3-(4-(2-Chloro-5-iodobenzyl)phenoxy)tetrahydrofuran, ships in accordance with hazardous materials regulations. It is packaged securely in sealed containers, cushioned against breakage, and labeled for chemical safety. Shipping uses priority courier or specialized carriers, with documentation and tracking, ensuring safe delivery while meeting regulatory compliance for hazardous chemicals. |
| Storage | (S)-3-(4-(2-Chloro-5-iodobenzyl)phenoxy)tetrahydrofuran should be stored in a tightly sealed container, away from light and moisture, in a cool, dry, and well-ventilated area. Avoid exposure to heat and incompatible substances such as strong oxidizers. For long-term storage, refrigeration (2–8°C) is recommended to maintain stability and prevent degradation. Properly label and handle with appropriate safety precautions. |
| Shelf Life | Shelf life: Stable for 2 years when stored at 2–8°C, protected from light and moisture in tightly sealed containers. |
(S)-3-(4-(2-Chloro-5-iodobenzyl)phenoxy)tetrahydrofuran serves as a specialty intermediate across several precision chemical sectors, where its unique structure supports high-value transformations and end-formulation performance. As a dedicated manufacturer, we supply this material to select industries implementing advanced synthetic and formulation technologies. Below, we detail primary real-world downstream applications by scenario, highlighting regulatory integration, functional usage levels, incorporation points, and final output types.
This intermediate supports the synthesis of select chiral active pharmaceutical ingredients (APIs) in the small-molecule drug segment, where controlled stereochemistry and halogenation directly impact target activity. Major pharmaceutical manufacturers incorporate this raw material during multi-step synthesis pathways for drugs needing specific enantiomeric excess, leveraging its halogenated benzyl motif to construct complex, bioactive scaffolds.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
In agrochemical R&D and production, this compound enables synthesis of next-generation crop protection agents, with its halogenation profile and tetrahydrofuran ring essential during lead optimization. Producers rely on it for fine-tuning the reactivity and persistence of plant-incorporated protectants, especially where iodine and chlorine substitutions are critical for bioavailability or resistance management.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Manufacturers of organic light-emitting diode (OLED) components utilize this compound during small-molecule emitter and advanced host material synthesis. Its specific halogen function and cyclic ether backbone allow precise control over dopant dispersion in proprietary light-emitting or charge transport layers, directly affecting efficiency and operational stability in electronic display and lighting modules.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Producers of targeted contrast agents for diagnostic imaging—especially radio-iodine-labeled tracers—apply this intermediate for site-specific labeling and structural tuning. The compound’s iodine atom facilitates downstream radio-iodination or NMR-active functionalities, and its structural rigidity enhances in vivo metabolic profiles tailored to next-generation imaging techniques.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Competitive (S)-3-(4-(2-Chloro-5-iodobenzyl)phenoxy)tetrahydrofuran prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618005193850 or mail to sales8@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8618005193850
Email: sales8@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
In the world of chemical synthesis, every molecule brings a story to the bench. (S)-3-(4-(2-Chloro-5-iodobenzyl)phenoxy)tetrahydrofuran stands out not just for the tongue-twister of a name, but for the part it plays where precise molecular architecture is crucial. For those who spend their days overseeing batch reactors and chromatographs, this compound means more than an entry in a catalog. We watch it form under real conditions, see what it tolerates, spot impurities before others would suspect them, and make certain it meets defining standards with every run.
Chemists have chased selectivity and purity for decades, but not every compound rewards the effort in quite the same way. Take a closer look at this one: The tetrahydrofuran ring, together with the chloro-iodo benzyl group anchored at just the right spot, brings new options to building intermediates for pharmaceuticals and advanced materials. That precise (S)-stereochemistry doesn’t just add complication at the bench – it sets the pathway for downstream biological activity. Operating at scale, we learn pretty fast when a molecule like this starts misbehaving due to moisture, trace acids, or temperature swings, so every kilo matters.
Working with (S)-3-(4-(2-Chloro-5-iodobenzyl)phenoxy)tetrahydrofuran is both a test and a triumph for synthetic chemists. Over several production campaigns, teams here have explored the finer points of solid-liquid separation, solvent reclamation, and even the stubborn steps in chromatography that set the standard for optical rotation and HPLC profile. Unlike simpler ethers, this compound calls for nuanced handling right from coupling onwards. Once the initial core is constructed, the halogenated aromatic ring brings unique reactivity: Chlorine and iodine both demand an environment free of rogue nucleophiles and oxidative agents, so glassware and reagents get more scrutiny than in more forgiving syntheses.
Our methods center on batch synthesis for close temperature and agitation control. Over multiple crops, the crystallization of this compound presents tell-tale differences from similar ethers. The color and habit of the crystals often reveal lessons about subtle side reactions, sometimes invisible by NMR or mass spectrometry. This feedback loop between the lab and quality team creates a focus on outcomes, not just targets. While reaction times can stretch across shifts, every operator knows the satisfaction of a clean spot on TLC after hours of careful attention, especially with such a complex target.
Pharmaceutical synthesis owes as much to chiral centers as it does to clever functional groups. With the (S)-configuration set firmly into the tetrahydrofuran moiety, we’re not just making a molecule – we’re building a potential lead that fits and activates certain biological sites with the right three-dimensional character. Some related ethers arrive as racemates, but chiral separation translates into extra work, higher cost, and more waste. From the ground up, we've chosen the asymmetric routes and catalysts that let us walk straight to the desired stereochemistry, skipping the waste and complexity of resolution.
Every campaign begins with thorough checks of precursor chirality, and the NMR signals at the alpha-carbon serve as an early warning system for any racemization. Reagents see pre-qualification by both enantiomeric purity and water content. We use chiral HPLC as the mainstay for batch release, and every shift brings fresh technicians up to speed on why a few tenths of a percent in optical purity can make or break a shipment. For those developing new drug candidates, this consistency wins back weeks of method development time.
Anyone who has worked with halogenated aromatics knows the risks: small changes in storage or lab handling often spell big differences in batch reliability. The combination of tetrahydrofuran ring and dihalogenated benzyl group challenges even experienced operators. Keeping moisture at bay, both in feedstocks and glassware, has become a routine almost as essential as setting up the reactor itself. Some lessons required repeated failures during early attempts. Even the packaging reflects what we’ve learned about managing stability: We use sealed containers under dry nitrogen, never trusting the general rules that work for less sensitive compounds.
Direct sunlight and even short-term exposure to air can affect the sample’s shelf life. Part of the protocol before shipment includes checks by both IR spectrum and visual inspection for color shifts or sign of decomposition. As with other sensitive intermediates, we favor small-run, just-in-time schedules over long storage in inventory, which ensures material spends minimal time in containers. Customers planning to store it over several months have asked for recommendations on desiccant types and packaging configurations, and these conversations often prove more useful than any single technical data sheet.
Some compounds scale up with almost no surprises. This one is different. At low volumes, side products often lurk below detection limits, only to become apparent as faint bands on TLC plates or ghost peaks during scale-up QA. In our case, we’ve improved methods for solvent removal, phase separations, and temperature gradients during crystallization. Each campaign started with fresh process validation. Our QC team routinely evaluates GC-MS and NMR traces against historic “fingerprint” samples to spot the smallest impurity. This high standard often turns conversations with customers into mutual troubleshooting sessions. More than once, our openness about marginal byproducts led to changes both in our process and their downstream purification.
Avoiding cross-contamination with similar halogenated aromatics takes both diligent cleaning and a clear schedule for reactors. Each step’s byproducts sometimes require their own waste-handling solution. Staff rotate between analytical lab and plant floor, building practical intuition for problems like phase carryover or subtle shifts in melting point that betray an incomplete quench or poor solvent separation. Over time, we’ve gathered these patterns into a library, streamlining campaigns and training sessions for new team members.
It makes sense to ask what sets (S)-3-(4-(2-Chloro-5-iodobenzyl)phenoxy)tetrahydrofuran apart from more standard phenoxy ethers. Simple ethers may offer easier synthesis, with fewer bottlenecks or regulatory controls on halogenated feedstocks, but they seldom offer the exacting combination of reactivity and selectivity needed by drug discovery teams. The twin halogen pattern on the aromatic ring enables transformations that can open new synthetic pathways. Electrophilic substitution and cross-coupling chemistry benefit from strategically placed iodine and chlorine on the benzyl handle, offering more flexibility in subsequent steps such as Suzuki or Buchwald–Hartwig coupling.
For those layering more complexity onto scaffolds, the chiral, oxygen-rich tetrahydrofuran offers a defined three-dimensional anchor. It resists some hydrolytic pathways that breakdown open-chain analogs. Taking shortcuts by using acyclic or non-chiral versions typically leads to more downstream modifications or lower selectivity. Over time, the value emerges in lower attrition rates and fewer unsuccessful campaigns further along in development. We’ve seen researchers shift to this structure after several rounds of medicinal chemistry with simpler phenoxy ethers failed to yield hits or selectors with meaningful in vivo activity.
Customers often share updates on how this intermediate fits into early-stage candidate programs. Some use it to assemble kinase inhibitors, while others focus on antiviral scaffolds benefitting from the twin halogen substitution. We've tracked the pathway of this compound from the pilot plant straight to the hands of process chemists optimizing reactions for kilogram scale. Sending large batches for early toxicology studies, our own team saw firsthand how even small process variations translate to success or complications in the hands of a drug developer.
At the user’s end, the tetrahydrofuran ring brings solubility advantages, improving handling and mixing over more rigid aromatic ethers. The compound’s well-defined chiral center supports molecular docking and structure–activity studies prior to clinical selection. Some clients adapt our synthetic methods for their own variants, tweaking aromatic substitution or side chain configurations. These conversations turn into technical exchanges, with practical advice traded back and forth. Suppliers dealing in standard catalogs seldom see this feedback loop – we live it every cycle.
Repeatable quality doesn’t come from automation alone. The real advantage in working as the manufacturer comes from intimate knowledge of chemistry under actual conditions. Even the smallest changes in batch size, agitation rate, or cooling process can shift impurity profiles in subtle ways. Early campaigns taught us the hard lessons about overestimating the stability of certain intermediates and underestimating the sensitivity of trace iodine compounds.
We keep archives of chromatograms and batch records going back years, always pulling historic data when an unexplained anomaly surfaces. On more than one occasion, small inconsistencies in yield or purity have led to in-depth root-cause reviews. Operators who caught problems at the inspection stage receive direct feedback, and their suggestions translate into new checklists. Maintaining a learning culture across synthesis and quality teams makes it possible to stay ahead when the chemistry grows unpredictable.
We deal with requests for tighter specifications every month. Analytical teams spend as much time developing new test protocols as they do running routine checks. Most clients want more than a bland certificate—they ask for optical rotation, detailed impurity profiles, and even historical batch data to support regulatory filings. Being the original manufacturer means access to every process parameter, not just finished product data. That lets us answer questions quickly: Is this impurity isomeric or structural? Does it arise from batch-to-batch or scaling discrepancies? Supplying all this builds trust not only with regulatory reviewers but with chemists at the bench who depend on the material’s consistency for their own processes.
Over time, we have improved traceability by standardizing lot tracking and maintaining open lines of communication with both suppliers and clients. Raw material audits trace back to source where possible, favoring those with analytical transparency over price. Routine batch review meetings involve both operations and QA teams. CHN analysis, Karl Fischer, chiral GC, and X-ray crystallography often come up in process audit discussions not only as regulatory requirements, but as useful investigative tools. The hands-on approach extends past just specifications: We regularly gather feedback and address process improvements suggested by actual users, not just internal QA auditors.
Every batch released supports not only synthesis, but development timelines that can span years. Our part in the early-stage supply of (S)-3-(4-(2-Chloro-5-iodobenzyl)phenoxy)tetrahydrofuran shapes clinical development in ways often unrecognized by the public. A single contamination event might mean revisiting toxicological assessment or setting back IND filings. We’ve built redundant checks into every production batch and offer full analytical dossiers for regulatory review by design. Clients sometimes invite our technical team to support method validation or handle unforeseen process deviations during scale-up. In the world of specialty intermediates, these shared experiences create a sense of partnership that goes well beyond a normal supplier–customer relationship.
Mutual reliability comes up in every audit and face-to-face review. As the direct producer, we have real-time insight into not only synthesis, but market trends, evolving regulations for halogenated compounds, and sustainability practices. For example, handling waste streams that contain iodinated byproducts triggers special compliance routines, and we’ve discussed recovery programs that minimize environmental risk while lowering disposal costs. It’s not enough to cite compliance; producing these complex molecules responsibly is part of the day-to-day narrative here.
Part of the reward in making (S)-3-(4-(2-Chloro-5-iodobenzyl)phenoxy)tetrahydrofuran comes from finding ways to improve efficiency and sustainability. Plant engineers and chemists work together on solvent swaps, alternative catalysts, and optimized crystallizations. Early reliance on palladium routes gave way to exploring lower-cost, less toxic metal systems. We’ve transitioned to greener solvents whenever impurity profiles allow, always documenting shifts in yield or selectivity.
Tech transfer brings its own challenges. Experiences with scale transitions—both up and down—have pointed out strengths and weak points in our chosen synthetic schemes. Identifying bottlenecks lets the team propose re-engineered processes that save energy, increase safety, or reduce off-line purification steps. Incoming suggestions from customers and internal operators play equal roles in guiding the next set of trials. No automated system can replace the intuition developed over dozens of scale-ups and process tweaks.
Each compound at the intersection of halogenated aromatics and chiral ethers draws increased attention from regulatory agencies and NGOs focused on safe chemical production. We’ve adopted continuous monitoring for waste streams, and hold routine site audits to ensure full documentation for batch genealogy and raw materials. Packaging teams routinely evaluate new barrier materials and secondary containment, always guided by updates from transport safety partners and real-world observations.
Researchers working with us depend on reliable access to new analogues and derivatives. We’ve opened controlled programs for customers interested in customization, such as different halogen patterns or tweaks in the ring system, drawing on existing infrastructure and experience to offer more than a standard catalog approach. Every customization goes through risk assessment, cross-discipline review, and client input meeting before scale-up even begins.
Working as the actual manufacturer means seeing the entire journey of (S)-3-(4-(2-Chloro-5-iodobenzyl)phenoxy)tetrahydrofuran, not just a step in a supply chain. Project stories from process chemists get traded at team meetings, and the question “What could we have done better?” never gets old. We recognize that for every interruption avoided or impurity tracked down, both sides benefit. Open dialogue and shared expertise go further than a shipment or COA ever could. Our experience tells the story behind every batch – sometimes hard-fought, never routine, always focused on the actual needs of chemists working to invent what comes next.